170 related articles for article (PubMed ID: 8642360)
1. Treatment of Parkinson's disease.
Bergus G
J Fam Pract; 1996 May; 42(5):457-8. PubMed ID: 8642360
[No Abstract] [Full Text] [Related]
2. [Drug therapy of Parkinson disease].
Dietrichs E
Tidsskr Nor Laegeforen; 1992 Oct; 112(24):3106-9. PubMed ID: 1471089
[TBL] [Abstract][Full Text] [Related]
3. (-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment.
Knoll J
Biomed Pharmacother; 1996; 50(6-7):315-7. PubMed ID: 8952875
[No Abstract] [Full Text] [Related]
4. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
Rinne UK
Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
[No Abstract] [Full Text] [Related]
5. Single vs multiple daily dosing of aminoglycosides.
Newton W
J Fam Pract; 1996 May; 42(5):456-7. PubMed ID: 8642359
[No Abstract] [Full Text] [Related]
6. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
Larsen JP; Boas J
Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
[TBL] [Abstract][Full Text] [Related]
7. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
8. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
Amato L; Nava L; Rizzo M; Piccoli F
Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
[No Abstract] [Full Text] [Related]
9. Parkinson's disease in the elderly: current management strategies.
Aminoff MJ
Geriatrics; 1987 Jul; 42(7):31-7. PubMed ID: 3110015
[TBL] [Abstract][Full Text] [Related]
10. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
Olanow CW; Godbold JH; Koller W
BMJ; 1996 Mar; 312(7032):702-3; author reply 704-5. PubMed ID: 8597746
[No Abstract] [Full Text] [Related]
11. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
Stryjer R; Klein C; Treves TA; Rabey JM
Acta Neurol Scand; 2005 Feb; 111(2):89-94. PubMed ID: 15644067
[TBL] [Abstract][Full Text] [Related]
12. [Daily defined doses of parkinsonian drugs in Alcoi].
Manzanares R; Matías-Guiu J; Provencio R; Falip R; López-Arlandis J; Martín R; Ruiz C
Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923
[TBL] [Abstract][Full Text] [Related]
13. [Therapy for patients with early-stage Parkinson's disease].
Tanaka M; Okamoto K
Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1426-31. PubMed ID: 13677890
[No Abstract] [Full Text] [Related]
14. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P; Oakes D; Cui L
Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
[TBL] [Abstract][Full Text] [Related]
15. Strategies in the treatment of early Parkinson's disease.
Rinne UK
Acta Neurol Scand Suppl; 1993; 146():50-3. PubMed ID: 8101417
[TBL] [Abstract][Full Text] [Related]
16. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
Mizuno Y; Kondo T; Takubo H; Yokochi F
No To Shinkei; 1996 May; 48(5):467-72. PubMed ID: 8672306
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of selegiline in the early and late phases of Parkinson's disease.
Csanda E; Tárczy M
Adv Neurol; 1993; 60():672-5. PubMed ID: 8420208
[No Abstract] [Full Text] [Related]
18. Selegiline and mortality in Parkinson's disease.
Olanow CW; Fahn S; Langston JW; Godbold J
Ann Neurol; 1996 Dec; 40(6):841-5. PubMed ID: 9007088
[No Abstract] [Full Text] [Related]
19. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
[TBL] [Abstract][Full Text] [Related]
20. [Changing drug therapy of Parkinson disease].
Rinne UK
Duodecim; 1993; 109(20):1763-8. PubMed ID: 7736999
[No Abstract] [Full Text] [Related]
[Next] [New Search]
